What MedPacto does

MedPacto is a clinical-stage biotechnology company founded in 2013 and headquartered in Seocho-gu, Seoul, South Korea, that develops biomarker-guided precision oncology therapeutics through a TGF-β signaling inhibition platform. Its lead asset, Vactosertib (TEW-7197), is an oral selective TGF-β receptor I (ALK5) kinase inhibitor designed to neutralize tumor microenvironment immunosuppression, enhance immune-cell tumor killing, suppress metastasis, and break down stromal barriers, enabling combination with immunotherapies, targeted therapies, and chemotherapies across multiple solid tumor indications. The pipeline includes three additional first-in-class candidates: MP010, a bifunctional TME-targeted trap combining TGF-β neutralization with EDB-FN tumor targeting; MP2021, an Fc-fusion protein targeting TM4SF19 for osteoporosis and inflammatory arthritis; and MA-B2/MO-B2, a BAG2-targeting antibody therapeutic with companion diagnostic. The company pursues co-development with global pharmaceutical partners — including MSD for Phase 3 Vactosertib + Keytruda in metastatic colorectal cancer, AstraZeneca for Imfinzi combinations in bladder cancer and NSCLC, and Samsung Biologics for antibody manufacturing — alongside investigator-initiated trials at Fred Hutchinson Cancer Research Center, Weill Cornell, and the Case Comprehensive Cancer Center. FDA has granted Vactosertib Orphan Drug Designations in osteosarcoma, pancreatic cancer and gastric cancer, plus Fast Track and Rare Pediatric Disease Designations for metastatic osteosarcoma; the EMA has granted Orphan Medicinal Product Designation for osteosarcoma.

MedPacto is pre-commercial, generating no product revenue. Its revenue model anticipates future income from product sales following regulatory approval, supplemented by upfront payments, milestone payments, and royalties from technology licensing and co-development agreements with global pharmaceutical companies. The company has secured approximately 74.1 billion KRW (~$55M) in late 2023 capital raise funding, with cash reserves of approximately 480 billion KRW as of 1H25, plus prior Series A/B funding of $16M, Series C funding of $25M in June 2019, a 100 billion KRW investment in December 2020, and $7.5M in funding for its US subsidiary Celloram in August 2020. The company listed on KOSDAQ (ticker 235980) in December 2019 at an IPO price of 40,000 KRW per share, and operates with 51–100 employees across headquarters in Seoul and its wholly-owned US subsidiary MedPacto Therapeutics Inc. (established 2021), alongside a 24%-owned US subsidiary Celloram Inc. (founded 2018).

Name

MedPacto

Legal name

주식회사 메드팩토 (MedPacto, Inc.)

Website

https://medpacto.com

Company type

Public

Founded year

2013

Operating status

Operating

Headcount range

51–100 employees

Short description

MedPacto is a clinical-stage Korean biotechnology company developing biomarker-guided precision oncology therapeutics, led by the TGF-β receptor I inhibitor Vactosertib now in a Phase 3 trial with MSD for metastatic colorectal cancer, alongside three additional first-in-class pipeline candidates spanning solid tumors, bone disease and companion diagnostics.

Ownership category

akta.pro rank

Product category

Clinical-stage Biopharmaceuticals (Oncology)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Translational Medicine & Biomarkers (HLAIALAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Clinical-stage biopharmaceuticals
• TGF-beta inhibitors
• Oncology drug development
• Biomarker-based precision medicine
• Cancer immunotherapy combinations

Headquarters

HQ city

Seocho

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Drug Development and Commercialization: MedPacto is a pre-commercial clinical-stage biopharmaceutical company. Revenue will be generated through product sales following regulatory approval, as well as upfront payments, milestone payments, and royalties from technology licensing and co-development partnerships with global pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

MedPacto is a clinical-stage biopharmaceutical company developing biomarker-based first-in-class therapeutics centered on TGF-β signaling inhibition for cancer and inflammatory diseases. Its lead asset, oral Vactosertib, is being advanced in monotherapy and combination regimens across multiple cancer types, supplemented by pipeline candidates MP010, MP2021, MA-B2, and MO-B2 companion diagnostic. The company generates near-term revenue through licensing, co-development milestones, and royalties, and plans future commercialization via partnerships with global pharmaceutical companies.

Product overview

MedPacto is a biomarker-based First-in-Class drug development company focused on innovative cancer therapeutics. The core product is Vactosertib, an oral TGF-β receptor I inhibitor, alongside next-generation pipeline candidates MP010 (TME-targeting bifunctional fusion protein), MP2021 (TM4SF19 inhibitor for bone diseases), MA-B2 (BAG2-targeting antibody therapeutic), and MO-B2 (companion diagnostic kit for breast cancer). The company develops treatments through genome-based approaches to overcome limitations of existing anticancer drugs and implements precision medicine through biomarker-based drug development.

Differentiator

Problem solved

Functional benefit

Brands

• Vactosertib (백토서팁): TGF-β receptor I inhibitor for cancer treatment - the company's lead pipeline candidate
• MP010
• MP2021
• MA-B2/MO-B2

Products and services

• Vactosertib (TEW-7197) (백토서팁) Oral, potent, and selective TGF-β Receptor I (ALK5) kinase inhibitor developed by MedPacto for the treatment of solid tumors including osteosarcoma, metastatic colorectal cancer (MSS), NSCLC, gastric cancer, pancreatic cancer, multiple myeloma, and desmoid tumors. It can be combined with immunotherapies, targeted therapies, and chemotherapies. Currently in Phase 2b/3 development with co-development partner Merck/MSD.
• MP010 Next-generation bifunctional fusion protein platform drug targeting the tumor microenvironment (TME). Combines a TGF-β trap with EDB-FN tumor-targeting to break down extracellular matrix barriers and activate immune cells locally against solid tumors. Indicated for solid tumor applications including pancreatic cancer.
• MP2021 First-in-class Fc-fusion protein targeting TM4SF19, a novel tetraspanin membrane protein, for the treatment of osteoporosis, inflammatory arthritis, bone metastatic disease, and muscle wasting conditions. Acts via dual mechanism on bone loss and inflammation.
• MA-B2 First-in-class antibody therapeutic targeting BAG2 protein to inhibit cathepsin B metastatic activity and block BAG2-mediated immunosuppression, activating the immune system against cancer, particularly for metastatic and recurrent disease settings.
• MO-B2 Companion diagnostic kit for the detection of BAG2 protein levels in serum using sandwich ELISA methodology. Used to predict breast cancer metastasis and recurrence, particularly for triple-negative breast cancer patients.

Quantifiable outcome

• 75% two-year overall survival in recurrent pulmonary metastatic osteosarcoma patients vs 40% historical controls (Phase IIb OST-HER2 immunotherapy trial by OS Therapies)
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Merck (MSD)coreStrategic or Co-development Partner · 14 December 2021Global Phase 3 co-development agreement for Vactosertib + Keytruda (pembrolizumab) combination therapy in metastatic colorectal cancer. MSD provides Keytruda at no cost for the trial (approximately 35% of Phase 3 costs). First time a Korean biotech company entered Phase 3 co-development with MSD. Additional Phase 1b/2a trials ongoing in NSCLC and other indications.
• Fred Hutchinson Cancer Research CenterminorStrategic or Co-development Partner · 1 October 2021Investigator-initiated clinical trial collaboration for NK cell therapy + Vactosertib combination in colorectal cancer and hematologic malignancies.
• Samsung BiologicsminorStrategic or Co-development Partner · 14 April 2021Contract manufacturing organization (CMO) agreement for antibody treatment development, leveraging Samsung Biologics' expertise in biopharmaceutical manufacturing.
• Merck (MSD) - Keytruda combinationcoreStrategic or Co-development Partner · 26 May 2020Clinical collaboration for Vactosertib + Keytruda (pembrolizumab) combination therapy in multiple cancer types including NSCLC and gastric cancer. Part of broader strategic partnership for combination therapy development.
• Fred Hutchinson Cancer Research Center - operating agreementminorStrategic or Co-development Partner · 22 January 2020Operating agreement establishing framework for clinical trial collaboration including NK cell therapy combinations with Vactosertib.
• AstraZeneca - Imfinzi combinationcoreStrategic or Co-development Partner · 24 July 2018Clinical trial collaboration for Vactosertib + Imfinzi (durvalumab) combination therapy in bladder cancer (urothelial carcinoma) and NSCLC. Phase 1b/2a trials conducted in Korea with top-line data presented in 2024.
• Celloram (U.S. subsidiary)coreOthers · 1 January 2018U.S. subsidiary established by MedPacto (24% ownership) with co-founder John Letterio from Case Western Reserve. Raised $7.5M in 2020. Focused on autoimmune diseases, cancer vaccines, and inflammatory diseases. Pipeline includes CLM-022 inflammasome inhibitor and tolerogenic dendritic cell therapies.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• MacroGenics: US clinical-stage immuno-oncology biotech developing antibody-based therapeutics including combinations with checkpoint inhibitors. Comparable business model as a clinical-stage IO platform company pursuing combination strategies with PD-1/PD-L1 agents.
• Scholar Rock: US clinical-stage biotech focused on TGF-β superfamily biology (latent TGF-β activation), with lead asset apitegromab in neuromuscular disease. Directly comparable as a TGF-β platform company advancing targeted therapeutics into Phase 3.
• Genexine: Korean clinical-stage biotechnology company developing immuno-oncology and immunology therapeutics with a comparable size, public KOSDAQ listing, and strategic overlap in cancer combination therapies. Direct overlap in Korean biotech peer set and former employer of MedPacto's new CEO.
• Genfit: French clinical-stage biopharmaceutical company focused on inflammatory and metabolic diseases, and current licensee of MedPacto's Celloram subsidiary's CLM-022 inflammasome inhibitor. Comparable as a clinical-stage partner with shared deal economics.

Emerging players

• BeiGene: Global oncology company with broad immuno-oncology pipeline including checkpoint inhibitors used in combination trials. Comparable as a peer that validates the immuno-oncology combination strategy MedPacto is pursuing.
• I-Mab Biopharma: Clinical-stage biotech developing immuno-oncology assets including bispecific antibodies and combinations. Comparable as an emerging player in the IO space pursuing global partnership opportunities with large pharma.
• Innovent Biologics: Chinese clinical-stage and commercial biotech with strong PD-1 combination pipeline. Comparable as an Asian emerging player developing IO combination therapies and pursuing global pharmaceutical partnerships.

Regional players

• Hanmi Pharmaceutical: Korean pharmaceutical innovator with multiple oncology and immunology pipeline assets. Comparable as a Korean regional player with similar pipeline strategies targeting global partnerships and out-licensing opportunities.
• Yuhan Corporation: Major Korean pharmaceutical company with growing oncology and innovative drug pipeline. Comparable as a domestic Korean partner with capacity to in-license or collaborate on MedPacto's pipeline assets in the Korean market.

Broad incumbents

• Eli Lilly (galunisertib historical): Large pharmaceutical company that historically developed galunisertib, a competing TGF-β receptor I inhibitor in oncology. Comparable as a broad incumbent whose TGF-β clinical outcomes inform the validation and competitive context for MedPacto's Vactosertib.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/medpacto

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedPacto